MediMabBio, a biotech startup with operations in both Korea and the UK, has successfully raised $3 million in pre-Series A investment. The investment was finalized on February 15, 2019, with contributions from Smilegate Investment and BNH Investment. The funds will be utilized to propel the development of an innovative cancer treatment.